Objectives: To measure plasma concentrations of Tumor Necrosis Factor Receptor 2 (TNFR2) in patients with acute leukemia, and to correlate the results with clinical features.
Material and Methods: Twenty-four patients with acute myeloid leukemia (AML), sixteen patients with acute lymphoblastic leukemia (ALL) and fifteen control subjects were included in the current study. TNFR2 was measured in plasma of all subjects by enzyme-linked immunosorbent assay.
Results: Plasma TNFR2 significantly increased in ALL compared to both control and AML cases.
Conclusions: TNFR2 may be used as a biomarker for differentiating between AML and ALL patients.
El Kramani N, Elsherbiny NM, El-Gayar AM, Ebrahim MA, AlGayyar MMH. Tumor Necrosis Factor Receptor 2: Its Clinical Significance and Clinicopathologic Correlation in acute leukemias. J App Pharm Sci, 2015; 5 (11): 079-083.
Year
Month